Skip to main content
. 2024 May 12;38:438–454. doi: 10.1016/j.bioactmat.2024.05.015

Fig. 5.

Fig. 5

Feb-1+MSCs+NPs treatment system reduces neuronal cell ferroptosis and modulates inflammation after spinal cord injury (a–b) Feb-1 inhibits ferroptosis in the HT22 cell line and VSC4.1 cell line (n = 6, one-way ANOVA, Tukey's post hoc tests, ****P < 0.0001). (c–d) Protein expression of GPX-4 in VSC4.1 cell line (n = 5, one-way ANOVA, Tukey's post hoc tests, *P < 0.05, and ***P < 0.001). (e–g) Dihydroethidium staining demonstrated that Feb-1 clears ROS in neuronal cell lines (n = 9, one-way ANOVA, Tukey's post hoc tests, ****P < 0.0001). (h–j) Protein expression of GPX-4 and xCT in Sham, SCI, and Feb-1 treatment groups 3 dpi (n = 9, one-way ANOVA, Tukey's post hoc tests, **P < 0.01, and ***P < 0.001). (k, m-n) Protein expression of iNOS and IL-1b in the Sham, SCI, and Feb-1 treatment groups 10 dpi (n = 9, one-way ANOVA, Tukey's post hoc tests, *P < 0.05, **P < 0.01, and ***P < 0.001). (l, o) The results of Nissl staining showed that different treatment regimens decreased nerve cell death and promoted neuronal recovery (n = 4, one-way ANOVA, Tukey's post hoc tests, *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001).